Aurinia Pharmace Stock Price, News & Analysis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced participation in two upcoming virtual investor conferences. Management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, 2021, at 2:55 pm ET, and at the Cantor Global Healthcare Conference on September 30, 2021, at 12:40 pm ET. Interested parties can access webcasts via the Aurinia website, where replays will also be available. The company focuses on treating serious diseases with high unmet medical needs, notably introducing an FDA-approved therapy for lupus nephritis.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will present at the H.C. Wainwright & Co. 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting September 13, 2021, at 3 PM ET. Interested parties can access it via the Aurinia corporate website. The company specializes in biopharmaceuticals, particularly focusing on therapies for serious diseases with high unmet medical needs, and has recently launched the first FDA-approved oral treatment for adult lupus nephritis.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has announced the acquisition of two assets, AUR200 and AUR300, aimed at enhancing its pipeline for rare autoimmune and kidney diseases. AUR200, a recombinant protein targeting BAFF/APRIL, was acquired for $750,000, with further regulatory milestone payments expected. AUR300, a peptide therapeutic modulating M2 macrophages, was licensed for an upfront fee of $6 million, with additional milestone payments. Both programs aim to address unmet medical needs in immunology and nephrology, with clinical development anticipated for 2023.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that its executive management team will participate in a fireside chat at the Virtual BTIG Annual Biotech Conference on August 10, 2021, at 2:50 p.m. ET. Interested parties can access the live webcast via the 'Investors' section on Aurinia's corporate website. Additionally, a replay will be provided. Aurinia is a biopharmaceutical company focused on therapies for serious diseases with high unmet medical needs, including its FDA-approved treatment, LUPKYNIS™ (voclosporin), for adult patients with active lupus nephritis.

Aurinia Pharmaceuticals (AUPH) reported its Q2 2021 financial results, showing significant growth due to the commercial launch of LUPKYNIS for lupus nephritis. Total revenue reached $6.6 million, a sharp increase from $29,000 in Q2 2020. The company anticipates annual net revenue of $40 to $50 million for LUPKYNIS in 2021, setting the stage for strong growth in 2022. However, net losses widened to $47 million or $0.37 per share, up from a loss of $26.5 million in the same quarter last year. Aurinia had $323.7 million in cash as of June 30, 2021, supporting its commercial and R&D activities.

Aurinia Pharmaceuticals (NASDAQ: AUPH) will announce its second quarter 2021 financial results on August 5, 2021, after market close. Management will host a conference call at 4:30 p.m. EDT to discuss these results and provide a business update. Interested participants are invited to join the call by dialing +1-877-407-9170 or via an audio webcast available on the company's website.

Aurinia is focused on therapies for serious diseases, particularly lupus nephritis, and has launched LUPKYNIS™, the first FDA-approved oral therapy for this condition.

Aurinia Pharmaceuticals (NASDAQ: AUPH) will voluntarily delist its common shares from the Toronto Stock Exchange effective July 30, 2021. This decision follows that over 94% of its trading volume over the past year occurred on the Nasdaq. The company believes that maintaining a dual listing is no longer justified by trading volume and expects the transition to a single listing to enhance shareholder value. The Nasdaq will continue to offer adequate trading access for Canadian investors. Shareholder approval is not needed due to the presence of an acceptable alternative market.

Aurinia Pharmaceuticals (NASDAQ: AUPH) has awarded five grants of $50,000 each to non-profit organizations for patient navigation programs aimed at disadvantaged communities at risk of developing systemic lupus erythematosus (SLE) and lupus nephritis (LN). The programs will help improve access to diagnosis and treatment adherence. Launched on July 1, these initiatives will focus on cities including Atlanta, Brooklyn, Cleveland, Indianapolis, and Philadelphia. The goal is to enhance patient outcomes through education and support tailored to underserved populations.

Aurinia Pharmaceuticals (AUPH) announced that its partner, Otsuka Pharmaceutical Europe Ltd., has submitted a Marketing Authorization Application for voclosporin to treat lupus nephritis to the European Medicines Agency. Voclosporin, approved by the FDA in January 2021, is currently marketed in the U.S. as LUPKYNIS. Aurinia's collaboration with Otsuka includes a $50 million upfront payment and potential milestone payments, with tiered royalties between 10-20% based on sales. Lupus nephritis significantly impacts patients, particularly among Black and Hispanic populations.